Start here
Overview
Clinical references note that SLC35A2-congenital disorder of glycosylation (SLC35A2-CDG, formerly known as congenital disorder of glycosylation type IIm) is an inherited disorder that causes neurological problems and other abnormalities. In practice, this disorder's clinical features and their severity vary among affected individuals. Evidence summaries report that individuals with SLC35A2-CDG typically develop clinical features of the condition early in infancy. This overview explains the usual pattern of SLC35A2-congenital disorder of glycosylation; it cannot determine whether one individual has the condition.
- Clinical references note that SLC35A2-congenital disorder of glycosylation (SLC35A2-CDG, formerly known as congenital disorder of glycosylation type IIm) is an inherited disorder that causes neurological problems and other abnormalities. In practice, this disorder's clinical features and their severity vary among affected individuals. Evidence summaries report that individuals with SLC35A2-CDG typically develop clinical features of the condition early in infancy. This overview explains the usual pattern of SLC35A2-congenital disorder of glycosylation; it cannot determine whether one individual has the condition.
- Clinical references note that In SLC35A2-CDG, medical imaging shows loss of tissue (atrophy) in parts of the brain called the cerebrum and cerebellum. Identifying SLC35A2-congenital disorder of glycosylation starts with the clinical pattern and a focused examination. A clinician chooses tests to answer a specific question, then interprets results alongside age, medicines, family history, exposures, and other conditions. No single investigation is appropriate for every person.
- Care for SLC35A2-congenital disorder of glycosylation depends on its cause, severity, organs involved, other health conditions, and the person's goals. Options can range from observation and symptom support to medicines, procedures, rehabilitation, or specialist follow-up. The safest plan is individualized; prescribed care should not be changed because another person had a different experience.
Do not wait for a website to decide
- Call local emergency services for collapse, new confusion, major breathing difficulty, uncontrolled bleeding, or symptoms that are severe and rapidly worsening.
- Evidence summaries report that they also have severe intellectual disability and delayed development, often only being able to sit or crawl and never developing meaningful speech. Seek prompt professional assessment when symptoms are new, persistent, or clearly worsening.
People can experience it differently
What symptoms can occur?
Evidence summaries report that SLC35A2-congenital disorder of glycosylation (SLC35A2-CDG, formerly known as congenital disorder of glycosylation type IIm) is an inherited disorder that causes neurological problems and other abnormalities. For patients and families, an important point is that this disorder's clinical features and their severity vary among affected individuals. Clinical references note that individuals with SLC35A2-CDG typically develop clinical features of the condition early in infancy. In practice, individuals with SLC35A2-CDG often have abnormal brain function (encephalopathy), unusual facial features, skeletal differences, and weak muscle tone (hypotonia) with poor head control. Symptoms can overlap with other illnesses, and their absence does not always rule the condition out.
Risk does not equal certainty
Causes and risk factors
What is known about the cause
Clinical references note that SLC35A2-congenital disorder of glycosylation (SLC35A2-CDG, formerly known as congenital disorder of glycosylation type IIm) is an inherited disorder that causes neurological problems and other abnormalities. In practice, individuals with SLC35A2-CDG typically develop clinical features of the condition early in infancy. Evidence summaries report that Seizures develop within the first months of life, often involving uncontrollable muscle stiffening (infantile spasms) that can switch to shorter episodes of muscle jerks (epileptic spasms) later in childhood. For patients and families, an important point is that they also have severe intellectual disability and delayed development, often only being able to sit or crawl and never developing meaningful speech. The cause of SLC35A2-congenital disorder of glycosylation may be established, multifactorial, or still uncertain. Biological mechanisms, inherited factors, infections, exposures, medicines, and related health conditions are considered only when they fit the evidence. A general description should not be used to assign a personal cause.
Factors associated with higher risk
Factors linked with SLC35A2-congenital disorder of glycosylation differ by subtype and population. A clinician may consider age, family history, relevant exposures, medicines, and related conditions, but the importance of each factor varies. Risk changes probability; it does not confirm a diagnosis or predict one person's course.
Risk is not a diagnosis
Who is more likely to be affected?
Factors linked with SLC35A2-congenital disorder of glycosylation differ by subtype and population. A clinician may consider age, family history, relevant exposures, medicines, and related conditions, but the importance of each factor varies. Risk changes probability; it does not confirm a diagnosis or predict one person's course.
Tests answer specific questions
Common tests and what they show
- Clinical assessment
Clinical references note that In SLC35A2-CDG, medical imaging shows loss of tissue (atrophy) in parts of the brain called the cerebrum and cerebellum. Identifying SLC35A2-congenital disorder of glycosylation starts with the clinical pattern and a focused examination. A clinician chooses tests to answer a specific question, then interprets results alongside age, medicines, family history, exposures, and other conditions. No single investigation is appropriate for every person.
- Purpose and limits of testing
Tests should confirm a working diagnosis, assess severity, identify complications, or rule out an important alternative. Not every person needs every available investigation, and a result must be interpreted in context.
Clinical assessment
How is it diagnosed?
Clinical references note that In SLC35A2-CDG, medical imaging shows loss of tissue (atrophy) in parts of the brain called the cerebrum and cerebellum. Identifying SLC35A2-congenital disorder of glycosylation starts with the clinical pattern and a focused examination. A clinician chooses tests to answer a specific question, then interprets results alongside age, medicines, family history, exposures, and other conditions. No single investigation is appropriate for every person.
Professional assessment matters
What else can look similar?
Several disorders can resemble SLC35A2-congenital disorder of glycosylation, and the useful comparison depends on the symptom pattern, age, timing, examination, medicines, exposures, and test findings. Similarity in a search result is not enough to distinguish them. A clinician should prioritize alternatives that are common, treatable, or dangerous to miss, then select only the investigations likely to change care.
Classification can guide care
Types, severity, or stages
Some people with SLC35A2-congenital disorder of glycosylation are classified by cause, clinical type, severity, affected body system, or stage. These labels can guide testing, treatment, monitoring, and prognosis, but they are not interchangeable. Ask which classification applies, what evidence supports it, and whether it may change as more information becomes available.
Shared decisions
What are the treatment options?
Care for SLC35A2-congenital disorder of glycosylation depends on its cause, severity, organs involved, other health conditions, and the person's goals. Options can range from observation and symptom support to medicines, procedures, rehabilitation, or specialist follow-up. The safest plan is individualized; prescribed care should not be changed because another person had a different experience.
Looking beyond today's visit
Outlook and follow-up
The outlook for SLC35A2-congenital disorder of glycosylation varies with cause, severity, age at onset, organs involved, other health conditions, access to care, and response to treatment. Population averages cannot forecast one person's result. A more useful discussion sets measurable goals, identifies complications worth monitoring, and agrees on a date to reassess the plan.
Recognizing important change
Possible complications
Potential complications of SLC35A2-congenital disorder of glycosylation depend on the disease mechanism, severity, delay before treatment, and effects of therapy. Follow-up aims to identify important change early without testing for every theoretical problem. Ask which two or three complications are most relevant, what warning signs they cause, and whether scheduled examination or laboratory monitoring is needed.
Practical support
Self-management
For SLC35A2-congenital disorder of glycosylation, use the monitoring and follow-up plan agreed with the clinical team. Keep an accurate medicine list, note possible side effects, and record meaningful changes in symptoms or daily function. Not every case of SLC35A2-congenital disorder of glycosylation can be prevented. Where modifiable risks or screening options exist, a clinician can help decide which steps are relevant. Appropriate follow-up and early review of new problems can reduce avoidable harm. Home observations are most useful when they support a clinical decision; repeated checking without a plan can increase anxiety and may still miss important change.
Long-term health
Living with the condition
Living with SLC35A2-congenital disorder of glycosylation may affect energy, sleep, mobility, school, work, relationships, or emotional wellbeing, although the impact varies widely. Tell the care team what has become difficult rather than reporting test values alone. Ask which activities are safe, what support is available, and how progress will be measured. Reliable peer support can reduce isolation, but another person's diagnosis or treatment should not be copied as a personal plan.
Practical, evidence-based choices
Food and nutrition
There is no universal food plan that cures SLC35A2-congenital disorder of glycosylation. Nutrition advice should reflect the condition, medicines, swallowing or digestive symptoms, kidney and liver function, allergies, weight goals, culture, and access to food. Avoid restrictive diets or supplements promoted as substitutes for diagnosis or treatment; discuss any product that could interact with prescribed care.
Advice may need adapting
Children, pregnancy, and older adults
Children, older adults, pregnant or breastfeeding people, and those with kidney, liver, immune, developmental, or multiple health conditions may experience SLC35A2-congenital disorder of glycosylation differently. Test ranges, medicine doses, side-effect risks, and thresholds for urgent review can change in these groups. General information should therefore be checked against advice from a suitably qualified professional.
Separating evidence from assumptions
Common misconceptions
- One symptom or online checklist can prove SLC35A2-congenital disorder of glycosylation.
Symptoms often overlap across conditions. Diagnosis depends on context, examination, and appropriate testing.
- A treatment that helped another person is automatically safe for me.
Benefits, risks, doses, and monitoring depend on the individual, other conditions, and medicines.
Use appointment time well
Preparing for care
Before an appointment about SLC35A2-congenital disorder of glycosylation, write down when the problem began, how it has changed, what makes it better or worse, and how it affects ordinary activities. Bring previous reports, a full list of medicines and supplements, allergies, relevant family history, and two or three priorities. Ask what evidence supports the working diagnosis, which alternatives remain possible, what each test could change, and when follow-up should occur.
Care conversations
Questions to ask a health professional
- What findings support this diagnosis, and what important alternatives remain?
- Which tests are most likely to change the next decision?
- What are the realistic benefits, risks, and alternatives for each care option?
- Which changes require routine contact, prompt review, or emergency help?
Questions people often ask
10 common questions
What does SLC35A2-congenital disorder of glycosylation mean?
Clinical references note that SLC35A2-congenital disorder of glycosylation (SLC35A2-CDG, formerly known as congenital disorder of glycosylation type IIm) is an inherited disorder that causes neurological problems and other abnormalities. In practice, this disorder's clinical features and their severity vary among affected individuals. Evidence summaries report that individuals with SLC35A2-CDG typically develop clinical features of the condition early in infancy. This overview explains the usual pattern of SLC35A2-congenital disorder of glycosylation; it cannot determine whether one individual has the condition.
What symptoms can occur with SLC35A2-congenital disorder of glycosylation?
Evidence summaries report that SLC35A2-congenital disorder of glycosylation (SLC35A2-CDG, formerly known as congenital disorder of glycosylation type IIm) is an inherited disorder that causes neurological problems and other abnormalities. For patients and families, an important point is that this disorder's clinical features and their severity vary among affected individuals. Clinical references note that individuals with SLC35A2-CDG typically develop clinical features of the condition early in infancy. In practice, individuals with SLC35A2-CDG often have abnormal brain function (encephalopathy), unusual facial features, skeletal differences, and weak muscle tone (hypotonia) with poor head control. Symptoms can overlap with other illnesses, and their absence does not always rule the condition out.
What causes SLC35A2-congenital disorder of glycosylation?
Clinical references note that SLC35A2-congenital disorder of glycosylation (SLC35A2-CDG, formerly known as congenital disorder of glycosylation type IIm) is an inherited disorder that causes neurological problems and other abnormalities. In practice, individuals with SLC35A2-CDG typically develop clinical features of the condition early in infancy. Evidence summaries report that Seizures develop within the first months of life, often involving uncontrollable muscle stiffening (infantile spasms) that can switch to shorter episodes of muscle jerks (epileptic spasms) later in childhood. For patients and families, an important point is that they also have severe intellectual disability and delayed development, often only being able to sit or crawl and never developing meaningful speech. The cause of SLC35A2-congenital disorder of glycosylation may be established, multifactorial, or still uncertain. Biological mechanisms, inherited factors, infections, exposures, medicines, and related health conditions are considered only when they fit the evidence. A general description should not be used to assign a personal cause.
Who may be more likely to develop SLC35A2-congenital disorder of glycosylation?
Factors linked with SLC35A2-congenital disorder of glycosylation differ by subtype and population. A clinician may consider age, family history, relevant exposures, medicines, and related conditions, but the importance of each factor varies. Risk changes probability; it does not confirm a diagnosis or predict one person's course.
How do clinicians identify SLC35A2-congenital disorder of glycosylation?
Clinical references note that In SLC35A2-CDG, medical imaging shows loss of tissue (atrophy) in parts of the brain called the cerebrum and cerebellum. Identifying SLC35A2-congenital disorder of glycosylation starts with the clinical pattern and a focused examination. A clinician chooses tests to answer a specific question, then interprets results alongside age, medicines, family history, exposures, and other conditions. No single investigation is appropriate for every person.
How is SLC35A2-congenital disorder of glycosylation usually treated or managed?
Care for SLC35A2-congenital disorder of glycosylation depends on its cause, severity, organs involved, other health conditions, and the person's goals. Options can range from observation and symptom support to medicines, procedures, rehabilitation, or specialist follow-up. The safest plan is individualized; prescribed care should not be changed because another person had a different experience.
Can SLC35A2-congenital disorder of glycosylation be prevented or its risks reduced?
Not every case of SLC35A2-congenital disorder of glycosylation can be prevented. Where modifiable risks or screening options exist, a clinician can help decide which steps are relevant. Appropriate follow-up and early review of new problems can reduce avoidable harm.
What should I record between appointments?
Keep a short dated record of symptoms, functional impact, medicines and side effects, relevant measurements, and questions. A consistent summary is usually more useful than a large amount of unstructured information.
When should someone with possible SLC35A2-congenital disorder of glycosylation seek urgent help?
Use the warning signs near the top of this guide and any personal emergency plan. Severe new symptoms, rapid deterioration, collapse, confusion, major breathing difficulty, uncontrolled bleeding, or inability to remain safe require urgent assessment.
How can I make the next appointment more useful?
Before an appointment about SLC35A2-congenital disorder of glycosylation, write down when the problem began, how it has changed, what makes it better or worse, and how it affects ordinary activities. Bring previous reports, a full list of medicines and supplements, allergies, relevant family history, and two or three priorities. Ask what evidence supports the working diagnosis, which alternatives remain possible, what each test could change, and when follow-up should occur.
Editorial boundaries
About this guide
Maintained by whocure content team
Purpose Health education and appointment preparation; not individual diagnosis or treatment.
Language status English content is maintained separately from the Chinese edition.